Bolt Biotherapeutics SVP sells 7,842 shares

Bolt Biotherapeutics’ Senior VP, Finance reported ESPP share purchases and subsequent sales to cover RSU-related tax withholding.

Rhea-AI Filing Summary

Bolt Biotherapeutics, Inc. (BOLT) reported that Sarah Nemec, Senior VP, Finance and PAO, purchased 509 shares of common stock on June 5, 2026 at $3.876 per share through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). She later sold 843 shares on September 16, 2,922 shares on September 17, and 4,077 shares on September 18, 2026 at weighted average prices of $3.774, $3.3183 and $3.2364 per share, respectively, to cover tax withholding obligations arising from the vesting of restricted stock units granted on October 22, 2025. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 7,333 shares

Net Sell 4 txns

Insider Nemec Sarah

Role Senior VP, Finance and PAO

Bought 509 shs ($2K)

Sold 7,842 shs ($26K)

Type	Security	Shares	Price	Value
Sale	Common Stock F4	4,077	$3.2364	$13K
Sale	Common Stock F3	2,922	$3.3183	$10K
Sale	Common Stock F2	843	$3.774	$3K
Purchase	Common Stock F1	509	$3.876	$2K

Holdings After Transaction: Common Stock — 17,082 shares (Direct)

Footnotes (4)

1. F1. These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
2. F2. Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
3. F3. Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
4. F4. Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares purchased: 509 shares Purchase price: $3.876 per share Shares sold September 16, 2026: 843 shares +4 more

7 metrics

Shares purchased 509 shares Common stock acquired June 5, 2026 via Employee Stock Purchase Plan

Purchase price $3.876 per share Common stock purchase on June 5, 2026 under ESPP

Shares sold September 16, 2026 843 shares Common stock sold to cover RSU tax withholding at $3.774 weighted average

Shares sold September 17, 2026 2,922 shares Common stock sold to cover RSU tax withholding at $3.3183 weighted average

Shares sold September 18, 2026 4,077 shares Common stock sold to cover RSU tax withholding at $3.2364 weighted average

Total shares sold 7,842 shares Aggregate common stock sales on September 16–18, 2026

Net share change 7,333 shares decrease 509 shares bought and 7,842 shares sold across reported transactions

Key Terms

Employee Stock Purchase Plan, Rule 16b-3(c), restricted stock units, tax withholding obligations, +1 more

5 terms

Employee Stock Purchase Plan financial

"These shares were acquired under the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3(c) regulatory

"transactions that were exempt under Rule 16b-3(c)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

restricted stock units financial

"in connection with the vesting of the restricted stock units granted on October 22, 2025"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold by the reporting person to cover tax withholding obligations in connection"

weighted average sales price financial

"Represents weighted average sales price. These shares were sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BOLT’s Senior VP, Finance report in this Form 4?

The reporting officer disclosed one purchase of 509 shares on June 5, 2026 through the Employee Stock Purchase Plan and three sales totaling 7,842 shares on September 16–18, 2026, all in Bolt Biotherapeutics common stock.

Why did the BOLT insider sell shares in September 2026?

The filing states the 7,842 shares sold on September 16–18, 2026 were sold to cover tax withholding obligations in connection with the vesting of restricted stock units granted on October 22, 2025.

What prices were reported for the BOLT insider’s September 2026 stock sales?

The sales used weighted average sales prices: $3.774 per share on September 16, $3.3183 on September 17, and $3.2364 on September 18, 2026. Footnotes state the actual sale prices ranged within specified bands on each date.

How many BOLT shares did the insider buy under the Employee Stock Purchase Plan?

The officer acquired 509 shares of Bolt Biotherapeutics common stock on June 5, 2026 at $3.876 per share under the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).

Were the BOLT insider’s transactions made under a Rule 10b5-1 trading plan?

The Form 4 indicates no Rule 10b5-1 trading plan; the document-level checkbox for such a plan is marked false, and the footnotes describe the sales as covering RSU-related tax withholding obligations.

What is the net share change for the BOLT insider in this Form 4?

The reported transactions show a purchase of 509 shares and sales of 7,842 shares, resulting in a net decrease of 7,333 shares of Bolt Biotherapeutics common stock over the period covered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 06:05 PM Accepted by SEC EDGAR 09/21/2026 - 06:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nemec Sarah

(Last) (First) (Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP, Finance and PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		P(1)		509	A	$3.876	1,924	D
Common Stock	09/16/2026		S		843	D	$3.774(2)	24,081	D
Common Stock	09/17/2026		S		2,922	D	$3.3183(3)	21,159	D
Common Stock	09/18/2026		S		4,077	D	$3.2364(4)	17,082	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).

2. Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

3. Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

4. Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

	/s/ William P. Quinn, Attorney-in-Fact	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)